Yijie Zhou

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Mark C. Genovese, Roy Fleischmann, Bernard Combe et al. · The Lancet · 2018 · 443 citations

Medicine, Internal Medicine, Pharmacotherapy +11

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Roy Fleischmann, Aileen L. Pangan, In‐Ho Song et al. · Arthritis & Rheumatology · 2019 · 436 citations

Medicine, Pharmacology, Pharmacotherapy +16

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch et al. · The Lancet · 2018 · 397 citations

Medicine, Internal Medicine, Pharmacology +13

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

Kim Papp, Diamant Thaçi, Kristian Reich et al. · British Journal of Dermatology · 2015 · 268 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial

Jennifer Maloney, David I. Bernstein, Harold S. Nelson et al. · Annals of Allergy Asthma & Immunology · 2013 · 157 citations

Life Sciences, Pharmacology, Pharmacotherapy +7